IP Verse

Aav Vectors For Retinal And Cns Gene Therapy - EP3137497

The patent EP3137497 was granted to Genzyme on Mar 5, 2025. The application was originally filed on May 2, 2015 under application number EP15723386A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3137497

GENZYME
Application Number
EP15723386A
Filing Date
May 2, 2015
Status
Patent Maintained As Amended
Jan 31, 2025
Grant Date
Mar 5, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSJan 7, 2022LEEADMISSIBLE

Patent Citations (42) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008US64011-
DESCRIPTIONUS2002141980
DESCRIPTIONUS2006135945
DESCRIPTIONUS2007088295
DESCRIPTIONUS2007259031
DESCRIPTIONUS2009317417
DESCRIPTIONUS2014335054
DESCRIPTIONUS4692147
DESCRIPTIONUS5735815
DESCRIPTIONUS6042579
DESCRIPTIONUS6225291
DESCRIPTIONUS6566118
DESCRIPTIONUS6596535
DESCRIPTIONUS6723551
DESCRIPTIONUS6953575
DESCRIPTIONUS6989264
DESCRIPTIONUS6995006
DESCRIPTIONUS7125717
DESCRIPTIONUS7341577
DESCRIPTIONUS7351239
DESCRIPTIONUS7465583
DESCRIPTIONUS7629322
DESCRIPTIONUS7785888
DESCRIPTIONUS7790154
DESCRIPTIONUS7846729
DESCRIPTIONUS7922999
DESCRIPTIONUS8093054
DESCRIPTIONUS8137948
DESCRIPTIONUS8361457
DESCRIPTIONWO2004027019
DESCRIPTIONWO2006042090
DESCRIPTIONWO2009105690
DESCRIPTIONWO2010088560
DESCRIPTIONWO2010148143
DESCRIPTIONWO9810088
DESCRIPTIONWO9961066
INTERNATIONAL-SEARCH-REPORTEP1486567
INTERNATIONAL-SEARCH-REPORTWO2010093784
INTERNATIONAL-SEARCH-REPORTWO2013173129
OPPOSITIONEP1486567
OPPOSITIONWO2010093784
OPPOSITIONWO2013173129

Non-Patent Literature (NPL) Citations (84) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANDERSEN ET AL., CELL. MOL. NEUROBIOL., (1993), vol. 13, pages 503 - 15-
DESCRIPTION- BANKIEWICZ ET AL., EXP. NEUROL., (2000), vol. 164, pages 2 - 14-
DESCRIPTION- BOISON, D., EPILEPSIA, (2010), vol. 51, pages 1659 - 1668-
DESCRIPTION- BOSHART ET AL., CELL, (1985), vol. 41, pages 521 - 530-
DESCRIPTION- BOSSIS ET AL., J. VIROL., (2003), vol. 77, no. 12, pages 6799 - 810-
DESCRIPTION- CHRISTINE, C.W. ET AL., NEUROLOGY, (2009), vol. 73, pages 1662 - 1669-
DESCRIPTION- CLARK ET AL., HUM. GENE THER., (1999), vol. 10, pages 1031 - 1039-
DESCRIPTION- CONWAY, JE ET AL., J. VIROLOGY, (1997), vol. 71, no. 11, pages 8780 - 8789-
DESCRIPTION- COSTANTINI L C ET AL., GENE THERAPY, (2000), vol. 7, pages 93 - 109-
DESCRIPTION- Current Protocols in Molecular Biology, (1987), page 30-
DESCRIPTION- DALKARA D ET AL., MOLECULAR THERAPY, (2009), vol. 17, pages 2096 - 2102-
DESCRIPTION- DAVIDSON ET AL., PNAS, (2000), vol. 97, no. 7, pages 3428 - 32-
DESCRIPTION- EBERLING, J.L. ET AL., NEUROLOGY, (2008), vol. 70, pages 1980 - 1983-
DESCRIPTION- FAGAN, X.J.; AL-QURESHI, S., CLIN. EXPERIMENT. OPHTHALMOL., (2013), vol. 41, no. 5, pages 500 - 7-
DESCRIPTION- FIANDACA ET AL., NEUROIMAGE, (2009), vol. 47, no. 2, pages T27 - 35-
DESCRIPTION- FIANDACA, M.S. ET AL., NEUROIMAGE, (2009), vol. 47, no. 2, pages T27 - 35-
DESCRIPTION- FISHER ET AL., J. VIROL., (1996), vol. 70, pages 520 - 532-
DESCRIPTION- FORSAYETH, JR ET AL., MOL. THER., (2006), vol. 14, no. 4, pages 571 - 577-
DESCRIPTION- FUKUDA, A.M.; BADAUT, J., GENES, (2013), vol. 4, pages 435 - 456-
DESCRIPTION- GAO ET AL., PNAS, (2002), vol. 99, no. 18, pages 11854 - 6-
DESCRIPTION- GAO ET AL., PNAS, (2003), vol. 100, no. 10, pages 6081 - 6-
DESCRIPTION- GOSSEN ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 5547 - 5551-
DESCRIPTION- GOSSEN ET AL., SCIENCE, (1995), vol. 268, pages 1766 - 1769-
DESCRIPTION- GUO ET AL., GENE THER., (1996), vol. 3, no. 9, pages 802 - 10-
DESCRIPTION- HADACZEK ET AL., HUM. GENE THER., (2006), vol. 17, pages 291 - 302-
DESCRIPTION- HARVEY ET AL., CURR. OPIN. CHEM. BIOL., (1998), vol. 2, pages 512 - 518-
DESCRIPTION- KAPLITT, M.G. ET AL., LANCET, (2007), vol. 369, pages 2097 - 2105-
DESCRIPTION- KERN, A ET AL., J. VIROL., (2003), vol. 77, pages 11072 - 11081-
DESCRIPTION- KERN, A. ET AL., J. VIROLOGY, (2003), vol. 77, pages 11072 - 11081-
DESCRIPTION- KHANI, S.C ET AL., INVEST. OPHTHALMOL. VIS. SCI., (2007), vol. 48, no. 9, pages 3954 - 61-
DESCRIPTION- KHANI, S.C. ET AL., INVEST. OPHTHALMOL. VIS. SCI., (2007), vol. 48, no. 9, pages 3954 - 61-
DESCRIPTION- KIM ET AL., GENE, (1990), vol. 91, no. 2, pages 217 - 23-
DESCRIPTION- KOTIN, HUM. GENE THER., (1994), vol. 5, pages 793 - 801-
DESCRIPTION- KRAUZE ET AL., METHODS ENZYMOL., (2009), vol. 465, pages 349 - 362-
DESCRIPTION- MAGARI ET AL., J. CLIN. INVEST., (1997), vol. 100, pages 2865 - 2872-
DESCRIPTION- MANDEL, R.J., CURR. OPIN. MOL. THER., (2010), vol. 12, pages 240 - 247-
DESCRIPTION- MARTIN ET AL., HUMAN GENE THERAPY METHODS, (2013), vol. 24, pages 253 - 269-
DESCRIPTION- MCLAUGHLIN ET AL., J. VIROL., (1988), vol. 62, pages 1963 - 1973-
DESCRIPTION- ., Methods in Enzymology, ACADEMIC PRESS, INC.-
DESCRIPTION- ., Methods in Molecular Biology, HUMANA PRESS-
DESCRIPTION- MIYAZAKI, J. ET AL., GENE, (1989), vol. 79, no. 2, pages 269 - 77-
DESCRIPTION- MOVEMENT DISORDERS, (1996), vol. 11, pages 136 - 42-
DESCRIPTION- MULLER, O.J. ET AL., CARDIOVASCULAR RESEARCH, (2006), vol. 70, pages 70 - 78-
DESCRIPTION- NIWA ET AL., GENE, (1991), vol. 108, no. 2, pages 193 - 9-
DESCRIPTION- NO ET AL., "the tetracycline-repressible system", PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 3346 - 3351-
DESCRIPTION- OPIE, SR ET AL., J. VIROL., (2003), vol. 77, pages 6995 - 7006-
DESCRIPTION- "pages 1035-1038 and 1570-1580", Remington's Pharmaceutical Sciences, 15th Edition,, MACK PUBLISHING-
DESCRIPTION- PASSINI ET AL., J. VIROL., (2003), vol. 77, no. 12, pages 7034 - 40-
DESCRIPTION- PECHAN ET AL., GENE THER., (2009), vol. 16, pages 10 - 16-
DESCRIPTION- PEYMAN, G.A. ET AL., RETINA, (2009), vol. 29, no. 7, pages 875 - 912-
DESCRIPTION- PICCIOLI ET AL., NEURON, (1995), vol. 15, pages 373 - 84-
DESCRIPTION- PICCIOLI ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 5611 - 5-
DESCRIPTION- QING, K. ET AL., NAT. MEDICINE, (1999), vol. 5, pages 71 - 77-
DESCRIPTION- RABINOWITZ, J.E. ET AL., J. VIROL., (2002), vol. 76, no. 2, pages 791 - 801-
DESCRIPTION- SANFTNER, LM ET AL., EXP. NEUROL., (2005), vol. 194, no. 2, pages 476 - 483-
DESCRIPTION- SLOW ET AL., HUM. MOL. GENET., (2003), vol. 12, pages 1555 - 1567-
DESCRIPTION- STANEK ET AL., HUM. GENE THER., (2014), vol. 25, pages 461 - 474-
DESCRIPTION- SUMMERFORD, C. ET AL., NAT. MEDICINE, (1999), vol. 5, pages 78 - 82-
DESCRIPTION- SUMMERFORD, C.; R.J. SAMULSKI, J. VIROLOGY, (1998), vol. 72, pages 1438 - 1445-
DESCRIPTION- SUMMERFORD, C.; SAMULSKI, R.J., J. VIROL., (1998), vol. 72, no. 2, pages 1438 - 45-
DESCRIPTION- VAN RAAMSDONK ET AL., HUM. MOL. GENET., (2005), vol. 14, pages 3823 - 3835-
DESCRIPTION- VELDWIJK ET AL., MOL. THER., (2002), vol. 6, pages 272 - 278-
DESCRIPTION- WANG ET AL., GENE THER., (1997), vol. 4, pages 432 - 441-
DESCRIPTION- WANG ET AL., NAT. BIOTECH., (1997), vol. 15, pages 239 - 243-
DESCRIPTION- WANG Z. ET AL., GENE THER, (2003), vol. 10, pages 2105 - 2111-
DESCRIPTION- WU, Z. ET AL., MOLECULAR THERAPY, (2006), vol. 14, pages 316 - 327-
DESCRIPTION- XIAO ET AL., EXP. NEUROBIOL., (1997), vol. 144, pages 113 - 124-
DESCRIPTION- XIAO ET AL., JOURNAL OF VIROLOGY, (1998), vol. 72, pages 2224 - 2232-
DESCRIPTION- XIAO ET AL., J. VIROL., (1998), vol. 72, pages 2224 - 2232-
DESCRIPTION- XIE, Q. ET AL., PROC. NATL. ACAD. SCI., (2002), vol. 99, no. 16, pages 10405 - 10-
DESCRIPTION- YOUNG, J.E. ET AL., INVEST. OPHTHALMOL. VIS. SCI., (2003), vol. 44, no. 9, pages 4076 - 85-
INTERNATIONAL-SEARCH-REPORT- VANDENBERGHE LUK H ET AL, "Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (200608), vol. 12, no. 8, doi:10.1038/NM1445, ISSN 1078-8956, pages 967 - 971, XP002454221 [A] 1 * table 1 *
INTERNATIONAL-SEARCH-REPORT- ALLOCCA MARIACARMELA ET AL, "Novel adeno-associated virus serotypes efficiently transduce murine Photoreceptors", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (200710), vol. 81, no. 20, doi:10.1128/JVI.01327-07, ISSN 0022-538X, pages 11372 - 11380, XP002528463 [X] 1-3,5-7,9,11,14-16,31-35,41,250,262,263,267-271,276,278,280,282,283,285,297,306,307 * page 11372 - page 11379 * [Y] 4,8,10,12,13,17-19,26-29,36-40,42-46,87-102,108-111,113-125,277,279,281,284,286-290,302-305 [I] 30,112
OPPOSITION- ARNETT et al., "Herparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction", Gene Therapy, (20130000), vol. 20, pages 497 - 503, XP055898583-
OPPOSITION- COUNE et al., "Parkinson's Disease: Gene Therapies", Cold Spring Harb Perspect Med, (20120000), pages 1 - 16, XP055898557-
OPPOSITION- MASTAKOV et al., "Recombinant Adeno-associated Virus Serotypes 2- and 5-Mediated Gene Transfer in the Mammalian Brian: Quantitative Analysis of Heparin Co-infusion", Mol Ther., (20020400), vol. 5, no. 4, pages 371 - 380, XP055898576-
OPPOSITION- MCLAUGHLIN et al., "Adeno-associated virus general transduction vectors: analysis of proviral structures", J. Virol., (19880000), vol. 62, no. 6, pages 1963 - 1973, XP002106651-
OPPOSITION- MURLIDHARAN et al., "Biology of adeno-associated viral vectors in the central nervous system", Front. Mol. Neurosci., (20140919), pages 1 - 9, XP055898563-
OPPOSITION- PURVES D et al., "The Retina", Neuroscience, (20010000), pages 1 - 3, XP055898537-
OPPOSITION- SAMULSKI R J; CHANG L-S; SHENK T, "HELPER-FREE STOCKS OF RECOMBINANT ADENO-ASSOCIATED VIRUSES: NORMAL INTEGRATION DOES NOT REQUIRE VIRAL GENE EXPRESSION", J. Virol., (19890000), vol. 63, pages 3822 - 3828, XP000283071-
OPPOSITION- Samulski R Jude; Muzyczka Nicholas, "AAV-mediated gene therapy for research and therapeutic purposes", Annu. Rev. Virol., (20140000), vol. 1, pages 427 - 451, XP055850562-
OPPOSITION- VANDENBERGHE et al., "Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid", Nature Medicine, (20060000), vol. 12, no. 8, pages 967 - 971, XP002454221
OPPOSITION- NGUYEN et al., "Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain", Neuroreport, (20010703), vol. 12, no. 9, pages 1961 - 1964, XP002974882
OPPOSITION- ALLOCCA et al., "Novel adeno-associated virus serotypes efficiently transduce murine Photoreceptors", Journal of Virology, (20070000), vol. 81, no. 20, pages 11372 - 11380, XP002528463

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents